Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, announced the closing of a registered direct offering that raised approximately $4 million in gross proceeds. The offering consisted of 3,669,725 shares of common stock, or pre-funded warrants in lieu thereof, priced at $1.09 per share. In a concurrent private placement, the company issued unregistered warrants to purchase up to 3,669,725 additional shares at the same exercise price, potentially providing another $4 million in gross proceeds if fully exercised for cash. Rodman & Renshaw LLC served as the exclusive placement agent.
The capital injection is significant for Lantern Pharma as it continues to develop its proprietary RADR artificial intelligence and machine-learning platform, which integrates large-scale genomic and biological data to identify patients most likely to benefit from its therapies and to guide biomarker-driven clinical development. The company’s pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI.
According to the announcement, the net proceeds will be used for working capital and other general corporate purposes. This funding comes at a critical time for the biotech sector, where access to capital is essential for advancing clinical trials and maintaining operations. For investors, the offering demonstrates continued interest in AI-driven drug development, a field that promises to reduce the cost and time associated with bringing new cancer therapies to market. The additional warrants provide a potential future cash infusion, which could further support Lantern’s research and development efforts.
The news was disseminated through NetworkNewsWire, a specialized communications platform focused on financial news and content distribution. NetworkNewsWire is part of the Dynamic Brand Portfolio at IBN, which offers a range of services including wire distribution through InvestorWire, article and editorial syndication to 5,000+ outlets, and social media distribution to millions of followers. The full press release can be viewed at https://nnw.fm/a9u8A, and the latest updates on Lantern Pharma are available in the company’s newsroom at https://nnw.fm/LTRN.
For the broader market, this offering underscores the ongoing trend of AI integration in biotechnology, where companies leverage machine learning to accelerate drug discovery and improve patient outcomes. As Lantern Pharma advances its pipeline, the success of its AI platform could have implications for how oncology therapies are developed and commercialized, potentially leading to more targeted and effective treatments. Investors and industry watchers will be monitoring the company’s progress closely, given the high stakes and competitive nature of cancer research.
